Transdermal Buprenorphine for the Treatment of Chronic Noncancer Pain in the Oldest Old

Gianni, Walter; Madaio, Angelo Raffaele; Ceci, Moira; Benincasa, Elena; Conati, Gianfranco; Franchi, F.; G, Galetti; Nieddu, Antonio; Salani, Bernardo; Zuccaro, Stefano Maria

doi:10.1016/j.jpainsymman.2010.06.015

Cited by 32 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31,33,50,52 All 12 of these studies also found transdermal buprenorphine to be well tolerated in the treatment of general chronic pain. 31,33,36,[40][41][42][48][49][50][51][52]55 All of the 15 studies examining chronic low back pain (10 studies) or osteoarthritis pain (5 studies) demonstrated effective pain relief for transdermal buprenorphine, including 1 osteoarthritis study that examined solely elderly populations. 14,34,35,37,38,43,44,46,47,53,54,[56][57][58][59] These studies also examined parameters associated with quality of life, and all 15 demonstrated improvements in activities of daily living (lifting, bending, working), sleep, and/or physical and mental health in response to treatment with transdermal buprenorphine.…”

Section: Transdermal Formulationmentioning

confidence: 97%

“…All 12 studies of general chronic pain demonstrated the efficacy of transdermal buprenorphine in pain relief, including 2 (17%) studies assessing an elderly population. 31,33,36,[40][41][42][48][49][50][51][52]55 Of these, 4 (33%) studies also observed various quality of life parameters, with all 4 showing improvements in general quality of life, sleep duration, and/or need for breakthrough analgesia. 31,33,50,52 All 12 of these studies also found transdermal buprenorphine to be well tolerated in the treatment of general chronic pain.…”

Section: Transdermal Formulationmentioning

confidence: 99%

“…31,33,36,[40][41][42][48][49][50][51][52]55 Of these, 4 (33%) studies also observed various quality of life parameters, with all 4 showing improvements in general quality of life, sleep duration, and/or need for breakthrough analgesia. 31,33,50,52 All 12 of these studies also found transdermal buprenorphine to be well tolerated in the treatment of general chronic pain. 31,33,36,[40][41][42][48][49][50][51][52]55 All of the 15 studies examining chronic low back pain (10 studies) or osteoarthritis pain (5 studies) demonstrated effective pain relief for transdermal buprenorphine, including 1 osteoarthritis study that examined solely elderly populations.…”

Section: Transdermal Formulationmentioning

confidence: 99%

“…In each of the 24 studies that also assessed safety, transdermal buprenorphine was considered well tolerated. [31][32][33][34][35][36][37][38][39][40][41][42][45][46][47][48][49][50][51][52][53][54][55]58 The most commonly reported adverse events in transdermal buprenorphine clinical trials were nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash. 23…”

Section: Transdermal Formulationmentioning

confidence: 99%

See 3 more Smart Citations

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

Pergolizzi¹,

Raffa²

2019

JPR

View full text Add to dashboard Cite

Background: Chronic pain is associated with decreased quality of life and is one of the most common reasons adults seek medical care, making treatment imperative for many aspects of patient well-being. Chronic pain management typically involves the use of Schedule II full μ-opioid receptor agonists for pain relief; however, the increasing prevalence of opioid addiction is a national crisis that is impacting public health and social and economic welfare. Buprenorphine is a Schedule III partial μ-opioid receptor agonist that is an equally effective but potentially safer treatment option for chronic pain than full μ-opioid receptor agonists. The purpose of this review is to provide an overview of the clinical efficacy and safety of the transdermal and buccal formulations of buprenorphine, which are approved by the Food and Drug Administration for chronic pain, compared with that of extended-release full μ-opioid receptor agonists. Methods: Controlled or randomized controlled clinical trial information was retrieved from EMBASE, Medline, and PubMed using the search terms "buprenorphine" AND "chronic" AND "pain." Results: A total of 33 clinical studies were ultimately used in this review, including 29 (88%) on transdermal buprenorphine and 4 (12%) on buprenorphine buccal film. Although the measure of pain intensity varied among studies, each of these 33 trials demonstrated efficacy for buprenorphine in pain relief. A total of 28 studies also assessed safety, with each concluding that buprenorphine was generally well tolerated. Conclusion: Comparison of current clinical data along with results of responder and safety analyses support the use of buprenorphine over full μ-opioid receptor agonists for effective preferential treatment of chronic pain; however, head-to-head clinical studies are warranted.

show abstract

Section: Transdermal Formulationmentioning

confidence: 97%

Section: Transdermal Formulationmentioning

confidence: 99%

Section: Transdermal Formulationmentioning

confidence: 99%

Section: Transdermal Formulationmentioning

confidence: 99%

See 2 more Smart Citations

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

Pergolizzi¹,

Raffa²

2019

JPR

View full text Add to dashboard Cite

show abstract

“…Opioids may be appropriate for use in the elderly under close supervision, sometimes at reduced doses [24], or as low-dose transdermal treatment, e.g., buprenorphine [73, 74]. Recently, tapentadol extended-release has shown promise in the treatment of moderate to severe chronic pain related to OA [75, 76].…”

Section: Current Analgesics Used To Treat Arthritis-related Painmentioning

confidence: 99%

Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs

Laar¹,

Pergolizzi²,

Mellinghoff³

et al. 2012

TORJ

121

View full text Add to dashboard Cite

Managing pain from chronic conditions, such as, but not limited to, osteoarthritis and rheumatoid arthritis, requires the clinician to balance the need for effective analgesia against safety risks associated with analgesic agents. Osteoarthritis and rheumatoid arthritis pain is incompletely understood but involves both nociceptive and non-nociceptive mechanisms, including neuropathic mechanisms. Prevailing guidelines for arthritis-related pain do not differentiate between nociceptive and non-nociceptive pain, sometimes leading to recommendations that do not fully address the nature of pain. NSAIDs are effective in treating the nociceptive arthritis-related pain. However, safety concerns of NSAIDs may cause clinicians to undertreat arthritis-related pain. In this context, combination therapy may be more appropriate to manage the different pain mechanisms involved. A panel convened in November 2010 found that among the currently recommended analgesic products for arthritis-related pain, fixed-low-dose combination products hold promise for pain control because such products allow lower doses of individual agents resulting in decreased toxicity and acceptable efficacy due to synergy between the individual drugs. Better evidence and recommendations are required to improve treatment of chronic arthritis-related pain.

show abstract

Buprenorphine Analgesia in Chronic Pain

Hans

2013

Handbook of Methadone Prescribing and Buprenorphine Therapy

View full text Add to dashboard Cite

Transdermal Buprenorphine for the Treatment of Chronic Noncancer Pain in the Oldest Old

Abstract: Our experience confirms the analgesic activity and safety of buprenorphine TDS in the elderly. There was an improvement in mood and a partial resumption of activities, with no influence on cognitive and behavioral ability.

Cited by 32 publications

References 23 publications

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>

Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs

Buprenorphine Analgesia in Chronic Pain

Contact Info

Product

Resources

About